glp 1 png GLP-1R and Diabetes PDB-101: Molecule of the Month:

Zepbound still covered for OSA, Wegovy for cardiovascular disease [14] Blue Cross Blue Shield of Michigan: Ended all GLP-1 weight loss coverage for fully-insured large groups on 1/1/2025 [2] Blue Shield of California: Limited coverage to Class III (morbid) obesity only as of 1/1/2025 [3] BCBS of Massachusetts: Ended coverage for Wegovy, Zepbound, Saxenda starting 1/1/2026 [4] California Medi-Cal projects saving $85M in 2025-26, rising to $790M by 2028-29

Spojina raziskovalne kakovosti

Pharmazie 76 , 6167 (2021)

Examining MT-II-induced dopamine release in the nucleus accumbens by in vivo microdialysis, studying how MC4R activation in the VTA alters dopamine neurone firing and downstream reward behaviour, and examining whether dopamine receptor antagonists attenuate the motivational components of MT-IIs pro-sexual and appetitive effects

& Poli, M

ROS damage cellular lipids, proteins, and DNA, also triggering further immune responses that target melanocytes